Clinical Evidence
Advanced CRT Optimization
Every patient deserves life-changing therapy. Abbott's next generation CRT-D solutions make it possible for you to achieve clinically meaningful outcomes:
100% of patients had a narrower QRS when SyncAV™ CRT technology was optimized1
CRT-induced QRS narrowing has been shown to improve clinical outcomes for heart failure patients2,3
22% fewer heart failure hospitalizations for patients with SyncAV CRT technology enabled vs. patients with the technology disabled4
This device is commercially available for use in select international markets.
References
- Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
- Canadian Cardiovascular Society. Clinical Significance of Electromechanical Dyssynchrony and QRS Narrowing in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. https://doi.org/10.1016/j.cjca.2018.10.019. Accessed February 25, 2019.
- Okafor O, Leyva F, Zegard A, et al. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J Am Heart Assoc. 2019;8:e013539. DOI:10.1161/JAHA.119.013539.
- Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://esc365.escardio.org/home. Accessed May 15, 2020.
MAT-2009189 v2.0